Sign In
Buy GLUE
$16.52
-6.16 (-27.16%)
At Close: Jul 31, 2026
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, inc
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
04:01pm, Monday, 15'th Dec 2025
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann
Monte Rosa: Looking Mispriced After Big Pharma Validation
04:36am, Sunday, 30'th Nov 2025
Monte Rosa Therapeutics (GLUE) is transitioning from an oncology focus to a next-gen immunology & inflammation (I&I) platform, with significant pharma partnerships. GLUE's pipeline features MRT-6160 (
BETTY NAMED CREATIVE AGENCY OF RECORD FOR GORILLA GLUE
09:00am, Wednesday, 19'th Nov 2025
Agency will partner with Gorilla Glue on creative campaigns that build on the brand's toughness equity MINNEAPOLIS , Nov. 19, 2025 /PRNewswire/ -- Betty, a Quad agency, today announced it has been nam
Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and at
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates
09:30am, Thursday, 06'th Nov 2025
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.29 per share a year ago.
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
07:00am, Thursday, 06'th Nov 2025
Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option ex
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Monday, 03'rd Nov 2025
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann
Brighton Jones LLC Acquires New Stake in Monte Rosa Therapeutics, Inc. $GLUE
03:32am, Sunday, 02'nd Nov 2025
Brighton Jones LLC bought a new position in shares of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) during the second quarter, according to its most recent disclosure with the Securities and Exchange C
MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model Data s
Monte Rosa: H1 2026 NEK7 Protein Degrader MRT-8102 Data Could Be Added POC
09:25am, Thursday, 18'th Sep 2025
Monte Rosa secured a second major Novartis deal, adding $120M upfront and up to $5.7B in milestones to its cash reserves. GLUE advances MRT-8102, a NEK7 molecular glue degrader, into Phase 1 trials ta
Monte Rosa Therapeutics And The Promise Of Molecular Glue Degraders
10:56am, Tuesday, 16'th Sep 2025
Monte Rosa Therapeutics shares jumped this week after the company expanded its collaboration with Novartis. The Novartis partnership brings significant upfront cash and external QuEEN platform validat
Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
10:51am, Tuesday, 16'th Sep 2025
GLUE surges 44% after sealing a $5.7B licensing deal with NVS to advance molecular glue degraders for immune diseases.
Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?
09:05am, Tuesday, 16'th Sep 2025
Monte Rosa Therapeutics (GLUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in th
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
07:00am, Monday, 15'th Sep 2025
Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa's growing preclinical immunology portfolio Monte Rosa
